Drugs / AR1005
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06537076 | Jan 2024 → Dec 2025 overdue | Lewy body dementia | Yonsei University | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AR1005 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06537076 ↗ |
| Action | Inhibit | “AR1005 inhibits sodium currents by selective binding to the inactive sodium channel, suppressing the release of the excitatory amino acid, glutamate.” NCT06537076 ↗ |